Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114


Identification of Novel Response and Predictive Biomarkers to Hsp90 Inhibitors Through Proteomic Profiling of Patient-derived Prostate Tumor Explants.

Nguyen EV, Centenera MM, Moldovan M, Das R, Irani S, Vincent AD, Chan H, Horvath LG, Lynn DJ, Daly RJ, Butler LM.

Mol Cell Proteomics. 2018 Aug;17(8):1470-1486. doi: 10.1074/mcp.RA118.000633. Epub 2018 Apr 9.


Evidence for efficacy of new Hsp90 inhibitors revealed by ex vivo culture of human prostate tumors.

Centenera MM, Gillis JL, Hanson AR, Jindal S, Taylor RA, Risbridger GP, Sutherland PD, Scher HI, Raj GV, Knudsen KE, Yeadon T; Australian Prostate Cancer BioResource, Tilley WD, Butler LM.

Clin Cancer Res. 2012 Jul 1;18(13):3562-70. doi: 10.1158/1078-0432.CCR-12-0782. Epub 2012 May 9.


Co-targeting AR and HSP90 suppresses prostate cancer cell growth and prevents resistance mechanisms.

Centenera MM, Carter SL, Gillis JL, Marrocco-Tallarigo DL, Grose RH, Tilley WD, Butler LM.

Endocr Relat Cancer. 2015 Oct;22(5):805-18. doi: 10.1530/ERC-14-0541. Epub 2015 Jul 17.


Constitutively-active androgen receptor variants function independently of the HSP90 chaperone but do not confer resistance to HSP90 inhibitors.

Gillis JL, Selth LA, Centenera MM, Townley SL, Sun S, Plymate SR, Tilley WD, Butler LM.

Oncotarget. 2013 May;4(5):691-704.


The anticancer drug AUY922 generates a proteomics fingerprint that is highly conserved among structurally diverse Hsp90 inhibitors.

Voruganti S, Lacroix JC, Rogers CN, Rogers J, Matts RL, Hartson SD.

J Proteome Res. 2013 Aug 2;12(8):3697-706. doi: 10.1021/pr400321x. Epub 2013 Jun 27.


Novel Hsp90 inhibitor NVP-AUY922 radiosensitizes prostate cancer cells.

Gandhi N, Wild AT, Chettiar ST, Aziz K, Kato Y, Gajula RP, Williams RD, Cades JA, Annadanam A, Song D, Zhang Y, Hales RK, Herman JM, Armour E, DeWeese TL, Schaeffer EM, Tran PT.

Cancer Biol Ther. 2013 Apr;14(4):347-56. doi: 10.4161/cbt.23626. Epub 2013 Jan 28.


Potent activity of the Hsp90 inhibitor ganetespib in prostate cancer cells irrespective of androgen receptor status or variant receptor expression.

He S, Zhang C, Shafi AA, Sequeira M, Acquaviva J, Friedland JC, Sang J, Smith DL, Weigel NL, Wada Y, Proia DA.

Int J Oncol. 2013 Jan;42(1):35-43. doi: 10.3892/ijo.2012.1698. Epub 2012 Nov 14.


Dysregulated fibronectin trafficking by Hsp90 inhibition restricts prostate cancer cell invasion.

Armstrong HK, Gillis JL, Johnson IRD, Nassar ZD, Moldovan M, Levrier C, Sadowski MC, Chin MY, Tomlinson Guns ES, Tarulli G, Lynn DJ, Brooks DA, Selth LA, Centenera MM, Butler LM.

Sci Rep. 2018 Feb 1;8(1):2090. doi: 10.1038/s41598-018-19871-4.


Proteomic analysis of proteome and histone post-translational modifications in heat shock protein 90 inhibition-mediated bladder cancer therapeutics.

Li QQ, Hao JJ, Zhang Z, Krane LS, Hammerich KH, Sanford T, Trepel JB, Neckers L, Agarwal PK.

Sci Rep. 2017 Mar 15;7(1):201. doi: 10.1038/s41598-017-00143-6.


Sensitization of multidrug-resistant human cancer cells to Hsp90 inhibitors by down-regulation of SIRT1.

Kim HB, Lee SH, Um JH, Oh WK, Kim DW, Kang CD, Kim SH.

Oncotarget. 2015 Nov 3;6(34):36202-18. doi: 10.18632/oncotarget.5343.


Inhibition of Hsp90 augments docetaxel therapy in castrate resistant prostate cancer.

Ku S, Lasorsa E, Adelaiye R, Ramakrishnan S, Ellis L, Pili R.

PLoS One. 2014 Jul 29;9(7):e103680. doi: 10.1371/journal.pone.0103680. eCollection 2014.


HSP90 inhibitors enhance differentiation and MITF (microphthalmia transcription factor) activity in osteoclast progenitors.

van der Kraan AG, Chai RC, Singh PP, Lang BJ, Xu J, Gillespie MT, Price JT, Quinn JM.

Biochem J. 2013 Apr 15;451(2):235-44. doi: 10.1042/BJ20121626.


Novel HSP90 inhibitors, NVP-AUY922 and NVP-BEP800, radiosensitise tumour cells through cell-cycle impairment, increased DNA damage and repair protraction.

Stingl L, Stühmer T, Chatterjee M, Jensen MR, Flentje M, Djuzenova CS.

Br J Cancer. 2010 May 25;102(11):1578-91. doi: 10.1038/sj.bjc.6605683.


Suppression of heat shock protein 27 using OGX-427 induces endoplasmic reticulum stress and potentiates heat shock protein 90 inhibitors to delay castrate-resistant prostate cancer.

Lamoureux F, Thomas C, Yin MJ, Fazli L, Zoubeidi A, Gleave ME.

Eur Urol. 2014 Jul;66(1):145-55. doi: 10.1016/j.eururo.2013.12.019. Epub 2013 Dec 29. Erratum in: Eur Urol. 2016 Jul;70(1):e27-e28.


Evaluation of prostate-specific antigen as a novel biomarker of Hsp90 inhibition.

Oikonomopoulou K, Soosaipillai A, Diamandis EP.

Clin Biochem. 2009 Nov;42(16-17):1705-12. doi: 10.1016/j.clinbiochem.2009.07.018. Epub 2009 Jul 23.


Sensitization of chemo-resistant human chronic myeloid leukemia stem-like cells to Hsp90 inhibitor by SIRT1 inhibition.

Kim HB, Lee SH, Um JH, Kim MJ, Hyun SK, Gong EJ, Oh WK, Kang CD, Kim SH.

Int J Biol Sci. 2015 Jun 11;11(8):923-34. doi: 10.7150/ijbs.10896. eCollection 2015.


NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models.

Jensen MR, Schoepfer J, Radimerski T, Massey A, Guy CT, Brueggen J, Quadt C, Buckler A, Cozens R, Drysdale MJ, Garcia-Echeverria C, Chène P.

Breast Cancer Res. 2008;10(2):R33. doi: 10.1186/bcr1996. Epub 2008 Apr 22.


Gene expression-based chemical genomics identifies heat-shock protein 90 inhibitors as potential therapeutic drugs in cholangiocarcinoma.

Chen MH, Lin KJ, Yang WL, Kao YW, Chen TW, Chao SC, Chang PM, Liu CY, Tzeng CH, Chao Y, Chen MH, Yeh CN, Huang CY.

Cancer. 2013 Jan 15;119(2):293-303. doi: 10.1002/cncr.27743. Epub 2012 Jul 18.


Hsp90 inhibitor 17-AAG inhibits progression of LuCaP35 xenograft prostate tumors to castration resistance.

O'Malley KJ, Langmann G, Ai J, Ramos-Garcia R, Vessella RL, Wang Z.

Prostate. 2012 Jul 1;72(10):1117-23. doi: 10.1002/pros.22458. Epub 2011 Dec 7.


Inhibition of HSP90 with AUY922 induces synergy in HER2-amplified trastuzumab-resistant breast and gastric cancer.

Wainberg ZA, Anghel A, Rogers AM, Desai AJ, Kalous O, Conklin D, Ayala R, O'Brien NA, Quadt C, Akimov M, Slamon DJ, Finn RS.

Mol Cancer Ther. 2013 Apr;12(4):509-19. doi: 10.1158/1535-7163.MCT-12-0507. Epub 2013 Feb 8.

Supplemental Content

Support Center